Currently, much research on ICIs for PD-1, CTLA-4, and PD-L1 is underway, and clinical trials have revealed their efficacy and safety in BLCA (Carosella et al., 2015; Farina et al., 2017; Hussain et al., 2018). This evidence concerns the gene CTLA4 and bladder transitional cell carcinoma.